WCMC logo
PMKB
  • WCMC logoPMKB
  • Genes
  • Variants
  • Interpretations
  • Tumor Types
  • Primary Sites
  • Activity
  • Login
NRAS
  • Information
  • View History
  • Pending Review
Interpretation 165
Tier 1
NRAS
Variants
NRAS G12A
NRAS G12V
NRAS G12D
NRAS G12C
NRAS G12S
NRAS G12R
NRAS G13D
NRAS G13C
NRAS G13S
NRAS G13R
NRAS G13A
NRAS G13V
NRAS codon(s) 12, 13, 61, 146 any
Primary Sites
Thyroid
Tumor Types
Follicular Carcinoma
Papillary Carcinoma
Interpretation

RAS mutations (HRAS, NRAS and KRAS) are found in all epithelial thyroid malignancies. The frequency of HRAS mutations in thyroid carcinomas is 4%. RAS mutations are identified in 10-20% of papillary carcinomas, 40-50% of follicular carcinomas and 20-40% of poorly differentiated and anaplastic carcinomas .

Citations
  1. Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71
  2. JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517
  3. De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62
  4. Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77
  5. Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47
Last updated: 2020-07-24 14:53:44 UTC
PMKB Bot
  • Genes
  • Variants
  • Interpretations
  • Tumor Types
  • Primary Sites
  • Activity

Disclaimer: You assume full responsibility for all risks associated with using this PMKB website. The Englander Institute for Precision Medicine at Weill Cornell Medicine makes no guarantee of the comprehensiveness, reliability or accuracy of the information on this website and assumes no responsibility for errors in the information associated with this web site. Healthcare providers and patients must integrate all clinical and laboratory findings as well as information from a variety of sources before deciding on appropriate clinical care options.


When using PMKB, please cite: Huang et al., JAMIA 2017


HELP
User Guide
Video Tutorial
INFO
About
Latest
API
Twitter
CONTACT US
Contact

Englander Institute for Precision Medicine
© Weill Cornell Medicine | Version 1.7.2Privacy PolicyTerms of use